ABVXABIVAX Société Anonyme

$116.50

$68.9652 weeks$145.31

Price

$116.50+66%1Y

1M-11%1Y+66%

Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.

Smart Score

Below average

3/10

Value14

Quality31

Momentum71

Growth-

Strongest Momentum, weakest Value · ranked vs Healthcare peers. The five questions below judge the company on its own terms.

What they do

We are a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. We focus on indications where existing treatments have left patients with significant unmet needs, and where we believe our investigational agents have the potential to be meaningfully differentiated from currently available therapies.

In the company’s own words · 20-F filed Mar 23, 2026 · SEC EDGAR

P/E (TTM)-

Market Cap$7.90B

1Y Return+66%

5Y Return-

For the full year FY2025, revenue was €5.6M (−55% year on year) and net income −€336M.